Clinical trials
Epidermolysis Bullosa Simplex clinical trials
Below are recruiting epidermolysis bullosa simplex clinical trials, each written for real people, not researchers. We’re tracking 5 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07027345RecruitingPhase 2
Topical TolaSure cream for epidermolysis bullosa simplex
This study tests a medicated cream called TolaSure on skin affected by epidermolysis bullosa simplex (EBS), a condition that causes fragile skin and blistering. The cream aims to reduce blistering and improve healing by targeting a faulty protein in the skin. It is for people with localized, intermediate, or severe EBS who are currently having active blistering.
Palo Alto, CaliforniaAges 2 years+ - NCT07482787RecruitingPhase 3
Study of SD-101 for epidermolysis bullosa in children
This trial tests a new medicine called SD-101 for children with epidermolysis bullosa (EB), a condition that causes fragile skin and blistering. It aims to see if SD-101 can help heal wounds and improve quality of life.
Rancho Santa Margarita, CaliforniaAges 4 weeks–12 years - NCT06509984RecruitingPhase 2
Testing apremilast for genetic EBS with frequent blisters
This study tests whether a daily pill called apremilast can reduce the number of new blisters in people with a genetic form of EBS (epidermolysis bullosa simplex). If you get more than 3 new blisters per day and have a confirmed KRT5 or KRT14 mutation, this trial may be a good fit.
Nice, FranceAges 6–99 - NCT06917690RecruitingPhase 3
Testing oleogel-S10 for epidermolysis bullosa in Japanese patients
This trial tests a gel called oleogel-S10 on wounds caused by a rare skin condition called epidermolysis bullosa (EB). It is only for people of Japanese descent who have a specific type of EB called junctional or dystrophic EB. The gel is put on the wound to help it heal.
FukuokaAges 3 weeks+ - NCT06136403RecruitingPhase 2
Deucravacitinib for genetic skin disorders
This study tests a medication called deucravacitinib for adults with rare genetic skin conditions that cause blisters or severe scaling. The goal is to see if it can reduce symptoms safely.
Nice, CHU de NICEAges 18–99
Hear when a new Epidermolysis Bullosa Simplex trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for epidermolysis bullosa simplex?
- Yes. Clin2 currently lists 5 recruiting epidermolysis bullosa simplex studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a epidermolysis bullosa simplex trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a epidermolysis bullosa simplex trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.